JP2020534007A - 変異型ウイルスタンパク質 - Google Patents

変異型ウイルスタンパク質 Download PDF

Info

Publication number
JP2020534007A
JP2020534007A JP2020516534A JP2020516534A JP2020534007A JP 2020534007 A JP2020534007 A JP 2020534007A JP 2020516534 A JP2020516534 A JP 2020516534A JP 2020516534 A JP2020516534 A JP 2020516534A JP 2020534007 A JP2020534007 A JP 2020534007A
Authority
JP
Japan
Prior art keywords
seq
amino acid
protein
sequence
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020516534A
Other languages
English (en)
Japanese (ja)
Inventor
オーレリー アルベルティーニ
オーレリー アルベルティーニ
イヴ ゴーダン
イヴ ゴーダン
エレーヌ ロー
エレーヌ ロー
ローラ ブロ
ローラ ブロ
ジョヴァン ニコリック
ジョヴァン ニコリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60153233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2020534007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2020534007A publication Critical patent/JP2020534007A/ja
Priority to JP2023138247A priority Critical patent/JP2023179436A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20245—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20262—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020516534A 2017-09-22 2018-09-24 変異型ウイルスタンパク質 Pending JP2020534007A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023138247A JP2023179436A (ja) 2017-09-22 2023-08-28 変異型ウイルスタンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306255 2017-09-22
EP17306255.5 2017-09-22
PCT/EP2018/075824 WO2019057974A1 (en) 2017-09-22 2018-09-24 GLYCOPROTEIN MUTATED FROM VESICULAR STOMATITIS VIRUS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023138247A Division JP2023179436A (ja) 2017-09-22 2023-08-28 変異型ウイルスタンパク質

Publications (1)

Publication Number Publication Date
JP2020534007A true JP2020534007A (ja) 2020-11-26

Family

ID=60153233

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020516534A Pending JP2020534007A (ja) 2017-09-22 2018-09-24 変異型ウイルスタンパク質
JP2023138247A Pending JP2023179436A (ja) 2017-09-22 2023-08-28 変異型ウイルスタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023138247A Pending JP2023179436A (ja) 2017-09-22 2023-08-28 変異型ウイルスタンパク質

Country Status (14)

Country Link
US (8) US12091434B2 (enExample)
EP (3) EP4446337A3 (enExample)
JP (2) JP2020534007A (enExample)
CA (1) CA3076094A1 (enExample)
DK (1) DK3684786T3 (enExample)
ES (1) ES2991089T3 (enExample)
FI (1) FI3684786T3 (enExample)
HR (1) HRP20241466T1 (enExample)
HU (1) HUE069207T2 (enExample)
LT (1) LT3684786T (enExample)
PL (1) PL3684786T3 (enExample)
PT (1) PT3684786T (enExample)
SI (1) SI3684786T1 (enExample)
WO (1) WO2019057974A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4446337A3 (en) * 2017-09-22 2025-01-08 Centre National de la Recherche Scientifique Mutated glycoprotein of vesicular stomatitis virus
EP3708176A1 (en) * 2019-03-15 2020-09-16 Centre National De La Recherche Scientifique -Cnrs- Mutant vsv ectodomain polypeptide and uses thereof
CA3140115A1 (en) 2019-05-23 2020-11-26 Massachusetts Institute Of Technology Ligand discovery and gene delivery via retroviral surface display
EP4013459B1 (en) * 2019-08-16 2025-07-23 Mayo Foundation for Medical Education and Research Chimeric vesiculoviruses and methods of use
JP2023509966A (ja) * 2020-01-10 2023-03-10 カロジェン コーポレイション 腫瘍溶解性ウイルス様小胞の組成物および使用方法
EP4100420A1 (en) * 2020-02-06 2022-12-14 Boehringer Ingelheim Vetmedica GmbH Polypeptides useful for detecting anti-rhabdovirus antibodies
WO2022013872A1 (en) * 2020-07-14 2022-01-20 Ichilov Tech Ltd. Pseudotyped viruses configured to express car in t-cells
EP4284821A1 (en) 2021-01-27 2023-12-06 Umoja Biopharma, Inc. Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
CN112852757A (zh) * 2021-02-01 2021-05-28 南京大学 一种制备新型溶瘤病毒EM/VSV-G Ad5sPVRCD137L的方法
US20240218390A1 (en) 2021-02-26 2024-07-04 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
BR112023021075A2 (pt) * 2021-04-16 2023-12-12 Massachusetts Inst Technology Método para liberar um ou mais ácidos nucleicos a uma célula-tronco hematopoiética, e, método para edição de gene em uma célula-tronco hematopoiética
KR20240112950A (ko) * 2021-12-06 2024-07-19 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 조작된 세포 진입에 의한 수용체-리간드 특이성의 발견을 위한 방법 및 조성물
IL313473A (en) 2021-12-15 2024-08-01 Interius Biotherapeutics Inc Pseudotyped viral particles, compositions comprising the same, and uses thereof
IL291148A (en) * 2022-03-06 2023-10-01 Noga Therapeutics Ltd Lentiviral vectors for in vivo targeting of hematopoietic cells
AU2023272490A1 (en) 2022-05-17 2024-12-12 Umoja Biopharma, Inc. Manufacturing viral particles
TW202409288A (zh) 2022-07-25 2024-03-01 美商英特瑞斯生物療法公司 突變多肽、包含該等突變多肽之組合物及其用途
WO2024050450A1 (en) 2022-08-31 2024-03-07 Gigamune, Inc. Engineered enveloped vectors and methods of use thereof
WO2024098038A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Polynucleotide construct and related viral vectors and methods
WO2024098028A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Lentiviral particles displaying fusion molecules and uses thereof
WO2024097992A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions
KR20250160369A (ko) 2023-01-27 2025-11-12 리제너론 파마슈티칼스 인코포레이티드 변형된 랩도바이러스 당단백질 및 이의 용도
WO2024196738A2 (en) * 2023-03-17 2024-09-26 Kelonia Therapeutics, Inc. In vivo daric
KR20250167052A (ko) * 2023-04-10 2025-11-28 선전 제노큐리 바이오테크 컴퍼니 리미티드 돌연변이형 vsvg 및 표적화 벡터
WO2024216227A1 (en) 2023-04-12 2024-10-17 Vyriad Cd3-redirected vectors, components thereof, and uses of the vectors and components thereof
WO2024238153A1 (en) 2023-05-15 2024-11-21 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd20 chimeric antigen receptors
WO2025006882A1 (en) * 2023-06-30 2025-01-02 The Children's Hospital Of Philadelphia Click chemistry assisted cell surface engineering for restoring lentivirus entry
WO2025017052A1 (en) * 2023-07-18 2025-01-23 Vivebiotech S.L. Purification resin and methods for using the same
TW202521554A (zh) * 2023-08-11 2025-06-01 美商克隆尼亞治療股份有限公司 用於修飾細胞的組成物
WO2025036498A1 (zh) * 2023-08-16 2025-02-20 深圳市济因生物科技有限公司 一种病毒载体及其在感染b细胞中的应用
WO2025072257A1 (en) * 2023-09-25 2025-04-03 Kelonia Therapeutics, Inc. Compositions for treating cancer
US12403194B2 (en) 2023-09-25 2025-09-02 Kelonia Therapeutics, Inc. Compositions for treating cancer
US20250101122A1 (en) 2023-09-25 2025-03-27 Kelonia Therapeutics, Inc. Antigen binding polypeptides
WO2025072615A1 (en) 2023-09-29 2025-04-03 Orbital Therapeutics, Inc. Improved methods of making rna by splinted ligation and compositions thereof
WO2025102013A1 (en) 2023-11-10 2025-05-15 Vyriad Rhabdovirus g proteins having one or more cysteine-rich regions and uses thereof
WO2025162379A1 (zh) * 2024-02-01 2025-08-07 深圳市济因生物科技有限公司 一种多肽及包含所述多肽基因的病毒载体
WO2025189142A1 (en) 2024-03-08 2025-09-12 Vyriad Membraned vesicles and purification methods thereof
WO2025212851A2 (en) 2024-04-03 2025-10-09 Orbital Therapeutics, Inc. mRNA COMPOSITIONS AND USES THEREOF IN VARICELLA ZOSTER VIRUS VACCINES
WO2025231174A1 (en) 2024-04-30 2025-11-06 Umoja Biopharma, Inc. Manufacturing viral particles
WO2025231185A1 (en) 2024-05-01 2025-11-06 Legend Biotech Ireland Limited Viral glycoprotein variants and uses thereof
WO2025235604A1 (en) 2024-05-08 2025-11-13 Umoja Biopharma, Inc. Fusion protein for use as immune cell engager
WO2025259931A1 (en) 2024-06-14 2025-12-18 Orbital Therapeutics, Inc. Compositions and methods for rna circularization
WO2025260074A1 (en) 2024-06-14 2025-12-18 Vyriad Multiplexing functional polypeptides and recombinant rhabdoviral g glycoproteins on enveloped delivery vehicles

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019380A2 (en) * 1999-09-17 2001-03-22 Pro-Virus, Inc. Oncolytic virus
JP2005516607A (ja) * 2002-02-07 2005-06-09 デルタ バイオテクノロジー リミテッド Ｈｉｖ阻害タンパク質
JP2005247757A (ja) * 2004-03-04 2005-09-15 Nikken Sohonsha Corp 抗ウイルス剤
US20080124357A1 (en) * 2006-07-25 2008-05-29 Jiansheng Yao Vaccines against vesicular stomatitis
EP2020444A1 (en) * 2007-08-03 2009-02-04 Institut Pasteur Defective non-integrative lentiviral transfer vectors for vaccines
JP2010535495A (ja) * 2007-08-03 2010-11-25 インスティチュート・パスツール レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用
JP2016501528A (ja) * 2012-12-12 2016-01-21 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド 脳癌の治療のための組成物及び方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
EP4446337A3 (en) 2017-09-22 2025-01-08 Centre National de la Recherche Scientifique Mutated glycoprotein of vesicular stomatitis virus

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019380A2 (en) * 1999-09-17 2001-03-22 Pro-Virus, Inc. Oncolytic virus
JP2005516607A (ja) * 2002-02-07 2005-06-09 デルタ バイオテクノロジー リミテッド Ｈｉｖ阻害タンパク質
JP2005247757A (ja) * 2004-03-04 2005-09-15 Nikken Sohonsha Corp 抗ウイルス剤
US20080124357A1 (en) * 2006-07-25 2008-05-29 Jiansheng Yao Vaccines against vesicular stomatitis
EP2020444A1 (en) * 2007-08-03 2009-02-04 Institut Pasteur Defective non-integrative lentiviral transfer vectors for vaccines
JP2010535495A (ja) * 2007-08-03 2010-11-25 インスティチュート・パスツール レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用
JP2016501528A (ja) * 2012-12-12 2016-01-21 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド 脳癌の治療のための組成物及び方法

Also Published As

Publication number Publication date
US20250171505A1 (en) 2025-05-29
US12410215B2 (en) 2025-09-09
US20240317812A1 (en) 2024-09-26
US12030915B2 (en) 2024-07-09
EP4446337A3 (en) 2025-01-08
PL3684786T3 (pl) 2024-12-16
EP3684786B1 (en) 2024-08-14
CA3076094A1 (en) 2019-03-28
US12410216B2 (en) 2025-09-09
US20240327467A1 (en) 2024-10-03
JP2023179436A (ja) 2023-12-19
US20240327466A1 (en) 2024-10-03
DK3684786T3 (da) 2024-10-28
US12297237B2 (en) 2025-05-13
LT3684786T (lt) 2024-11-11
ES2991089T3 (es) 2024-12-02
EP4446337A2 (en) 2024-10-16
WO2019057974A1 (en) 2019-03-28
FI3684786T3 (fi) 2024-11-04
HRP20241466T1 (hr) 2025-01-03
US12291551B2 (en) 2025-05-06
US20200216502A1 (en) 2020-07-09
US20250171504A1 (en) 2025-05-29
US12091434B2 (en) 2024-09-17
US20240317811A1 (en) 2024-09-26
EP4442816A2 (en) 2024-10-09
SI3684786T1 (sl) 2025-03-31
EP4442816A3 (en) 2025-01-08
US12269848B2 (en) 2025-04-08
EP3684786A1 (en) 2020-07-29
US12264180B2 (en) 2025-04-01
HUE069207T2 (hu) 2025-02-28
US20240092839A1 (en) 2024-03-21
PT3684786T (pt) 2024-10-30

Similar Documents

Publication Publication Date Title
JP2023179436A (ja) 変異型ウイルスタンパク質
Paterson et al. Fusion protein of the paramyxovirus SV5: destabilizing and stabilizing mutants of fusion activation
JP2024153613A (ja) 突然変異体ｖｓｖ細胞外ドメインポリペプチドおよびその使用
Manfredi et al. Incorporation of heterologous proteins in engineered exosomes
CN116622641A (zh) Ace2和tmprss2双过表达细胞系及其制备方法和应用
JP6692853B2 (ja) 立体構造的に特異的なウイルス免疫原
JP7542830B2 (ja) 分子の細胞内送達のための複合体
CN113880924A (zh) 一种SARS-CoV-2假病毒
US20250288662A1 (en) Multivalent display on enveloped particles with human oligomerization domains
HK40117175A (en) Mutated glycoprotein of vesicular stomatitis virus
Chen et al. The nuclear localization signal sequence of porcine circovirus type 2 ORF2 enhances intracellular delivery of plasmid DNA
HK40117176A (en) Mutated glycoprotein of vesicular stomatitis virus
WO2025076013A1 (en) Engineered middle east respiratory syndrome proteins and related methods
WO2025224710A1 (en) Engineered orthopoxvirus proteins and related methods
Liu et al. Effects of disulfide bridges in glycoprotein E1 on fusogenic activity of Rubella virus
Webb Viral Fusion Protein TM-TM Interactions: Modulators of Protein Function and Potential Antiviral Targets
Shokralla Characterization of the H10/A4 Region of Vesicular Stromatitis Virus G Protein and Effects of H2-H10/A4 Mutations of Fusogenic Functions
Chen Studies of the influenza virus entry mechanism
within Arenavirus Identification of an N-Terminal Trimeric

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230427

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20230524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230828

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231107

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251211